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Arterial chronic hypertension (HTN) is a well-known cardiovascular risk factor for development of atherosclerosis. In order to
explain the relation between HTN and acute coronary syndromes the following factors should be considered: (1) risk factors
are shared by the diseases, such as genetic risk, insulin resistance, sympathetic hyperactivity, and vasoactive substances (i.e.,
angiotensin II); (2) hypertension is associated with the development of atherosclerosis (which in turn contributes to progression of
myocardial infarction). From all the registries and the data available up to now, hypertensive patients with ACS are more likely to be
older, female, of nonwhite ethnicity, and having a higher prevalence of comorbidities. Data on the prognostic role of a preexisting
hypertensive state in ACS patients are so far contrasting. The aim of the present paper is to focus on hypertensive patients with
ACS, in order to better elucidate whether these patients are at higher risk and deserve a tailored approach for management and
followup.
1. Introduction
Arterial chronic hypertension (HTN) is one of the estab-
lished cardiovascular risk factors for development of
atherosclerosis [1] and an increased incidence of peripheral
vascular disease [2], cerebrovascular disease [3], chronic
renal disease [4], and coronary artery disease [5]. It is also an
important risk factor for heart failure, myocardial infarction,
stroke, and cardiovascular death [6, 7].
In patients with acute myocardial infarction (AMI),
the prevalence of antecedent hypertension varies from 31
to 59% [8, 9]. According to the available evidence, it is
not clear whether previously known hypertensive patients
have an increased rate of adverse outcomes after AMI
including stroke, heart failure, and cardiovascular death [10].
Conversely, in non-ST elevation acute myocardial infarction
(NSTEMI), HTN is an independent factor for major short-
and long-term cardiac adverse outcome [11].
So far, data on long-term prognostic impact of hyper-
tension in patients with acute coronary syndrome (including
ST-elevation myocardial infarction (STEMI), NSTEMI, and
unstable angina) are still controversial, and scarce data are
available up to now. The aim of the present paper is to
focus on hypertensive patients with ACS, in order to better
elucidate whether these patients are at higher risk and
deserve a tailored approach for management and followup.
2. Epidemiology and Prevalence of HTN
in Patients with Acute Coronary Syndromes
Arterial hypertension is one of the main factors leading to
atherogenesis and the development of vulnerable plaques
whose instability or rupture (which in turn results in
thrombosis and vessel occlusions) are responsible for the
development of acute coronary syndromes (ACS).
In the general population, the prevalence of hypertension
rises progressively with age in both men and women, but
it is higher at all ages in blacks in whom it is a stronger
risk factor for coronary artery disease in respect to whites.
About 54% of the United States population aged 65 to 74
years is hypertensive while among blacks the prevalence
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of hypertension is 72% [12]. The age- and sex-adjusted
prevalence of hypertension (at the 140/90 mm Hg threshold)
is 28% in the North American countries and 44% in the
European countries [13].
In GUSTO-1 trial, 41021 STEMI patients who presented
within 6 hours of symptom onset were randomized to receive
different thrombolytic regimens: in this population the
prevalence of a history of previous hypertension was 38.1%
(15544 of 41021) [14]. In the GISSI-2 (Gruppo Italiano per
lo Studio della Streptochinasi nell’Infarto) which included
20491 patients with STEMI randomized to a 2×2 protocol of
thrombolysis, a history of HTN was present in about 35% of
the whole population [15]. However, to date, the prevalence
of arterial hypertension in patients with acute myocardial
infarction (AMI) has not been adequately investigated, since
most data were obtained from studies performed in the
prefibrinolytic era (when drugs such as aspirin, statins, or
beta-blockers were not yet part of the routine therapeutic list
and few diagnostic or interventional procedures were carried
out) or from clinical trials in which the patient characteristics
differed considerably from those found in routine clinical
practice.
More recently, other studies focused on patients with
STEMI submitted to primary PCI [16, 17] in which a
previous history of hypertension was present in a range of
30–33%. The SYMPHONY trial [18] showed a prevalence of
HTN in STEMI patients of more than 50% (probably due
to different criteria of selection of the study population),
and a recent Spanish registry (PRIMVAC) reported a 46%
prevalence of hypertension in STEMI patients [19]. Similarly,
in a recent paper by our group, performed in 856 STEMI
patients all submitted to primary PCI, a previous history of
hypertension was detectable in 50.6% (median age 67 years)
[20].
From all the registries and the data available up to now
[12–20], hypertensive patients with STEMI are more likely
to be older, female, of non-white ethnicity, and having a
higher prevalence of comorbidities such as diabetes, hyperc-
holesterolemia, chronic renal failure, history of cardiac heart
failure, prior myocardial infarction, and prior myocardial
revascularization (angioplasty and stent implantation or
coronary artery bypass graft) [21].
In epidemiological studies performed in non-ST eleva-
tion myocardial infarction (NSTEMI) patients, chronic HTN
is the most prevalent risk factor being detectable in almost
two thirds of entire population [22]. This higher prevalence
of HTN in NSTEMI in respect to STEMI patients (about
70–75% versus 30–40%) could be justified by the fact that
NSTEMI patients are usually older and affected by more co-
morbidities in respect to STEMI patients.
3. Hypertension in STEMI: Main
Pathophysiologic Mechanisms
The relation between HTN and myocardial infarction can be
mainly explained underscoring two key factors: (1) common
risk factors shared by the two diseases, such as genetic risk
profiles, insulin resistance, sympathetic hyperactivity, and
vasoactive substances (i.e., angiotensin II) and (2) hyper-
tension is associated with accelerated atherosclerosis, which
contributes to progression of myocardial infarction [23]
(Figure 1). Genetic risk factors, specifically gene polymor-
phisms of the angiotensinogen-converting enzyme (ACE)
and of the renin-angiotensin-aldosterone system (RAS),
could represent a “common milieu” responsible for both
hypertension and myocardial infarction, in a specific subset
of patients at high risk for cardiovascular complications
[24, 25].
Insulin resistance is another risk factor: [26] hyperin-
sulinemia is known to contribute to development of both
atherosclerosis and hypertension. In fact, decreased effect
of insulin on vascular smooth muscle tissue may result
in decreased ability to modulate vascular smooth muscle
cytoplasmic calcium and enhanced contractility (the so-
called “insulin resistance-induced hypertension”). Hyper-
insulinemia can also promote atherosclerosis and vascular
remodeling: in insulin-resistant patients the left ventricular
mass index is greater and the intimal-medial complex of
the common carotid artery and the frequency of plaques in
carotid artery are higher. In a recent study by our group in
253 nondiabetic STEMI patients submitted to percutaneous
coronary intervention, acute insulin resistance, as assessed by
HOMA index, was quite common and helped in the early
prognostic stratification, as it represented an independent
predictor of in-hospital mortality [27]: in this series 47.2%
of patients had a history of HTN on admission.
Furthermore, in hypertensive patients, an hyperactiv-
ity of sympathetic tone may promote atherosclerosis by
worsening insulin resistance, through sympathetic vasocon-
striction on glucose extraction in skeletal muscle, beta-
adrenoreceptor-mediated insulin resistance, and vascular
rarefaction because of the closure of the smaller vessels due
to vascular hypertrophy. Sympathetic hyperactivity itself also
contributes to a higher risk of sudden death, coronary spasm,
and coronary thrombosis [28].
The role of vasoactive substances, such as angiotensin
II, endothelin, natriuretic peptides, and nitric oxide, in
hypertensive patients is still under debate. Recent researches
underscored the role of vascular, local produced angiotensin
II, in opposition to its circulating form, in remodeling of
vascular structures such as aortic wall in animal models
[29]. One of the main factors leading to the development of
atherosclerosis in hypertensive patients’ vessels is mechanical
stress. It consists of three-dimensional forces: shear stress,
transmural pressure, and wall stress. Shear stress has been
shown to be responsible for the activation of angiotensin
II in HTN patients since cultured endothelial cells exposed
to shear stress have a higher expression of ACE gene.
Transmural pressure produces a “net effect of pressure” on
endothelial cells in vitro (in lack of other forces) and vascular
smooth cells, thus enhancing the production and growth
of new smooth cells. Lastly, stretch stress or wall stress,
in cultured vascular smooth muscle cells, can increase the
release of factors stimulating the DNA and protein synthesis;
stretched smooth cells in turn induce ACE activity and cell
growth, finally causing a muscle cell hypertrophy [30].
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Figure 1: Pathophysiological factors that link hypertension and acute myocardial infarction.
A chronic hypertensive state causes cardiac hypertro-
phy which is an independent risk factor for myocardial
infarction. Left ventricular hypertrophy is associated with
increased oxygen demand leading to the development of new
arterial vessels (collaterals) to supply the myocardium. This
collateral circulation, driven by pressure gradient, is more
effective in the subepicardial layer than in subendocardial
layer, which therefore results in being more exposed to
ischemia and infarction. During an acute coronary ischemic
event, systolic blood pressure and decreased wall tension of
ischemic area result in patency of small vessels, giving some
blood supply to the ischemic area. On the other side, large
reduction of diastolic blood pressure more often leads to
ischemia, despite the lack of total vessel occlusion [31].
Lastly, hypertensive state is characterized by hemorhe-
ological abnormalities, such as hyperviscosity, endothelial
dysfunction, and a prothrombotic state [32]; moreover it
has been demonstrated that vascular inflammation as well as
oxidative stress is more prevalent in HTN patients [33, 34].
4. Hypertension in STEMI: The Occurrence
of Complications
The clinical course of STEMI can be affected by several
complications, including (1) renal failure, due both to
contrast induced nephropathy and acute heart failure, (2)
cardiogenic shock, (3) major and minor bleedings causing
a new anemic state, and (4) acute glucose imbalance.
Regarding acute renal failure, in a recent paper by
Rembek et al. [35] comparing hypertensive and nonhy-
pertensive patients with STEMI, the hypertensive group
showed a higher incidence of previous renal diseases such as
nephrolithiasis and chronic glomerulonephritis and higher
baseline values of urea and creatinine serum level. Al Suwaidi
et al. [36] showed that reduced creatinine clearance was a
significant adverse prognostic factor for mortality, including
cardiovascular deaths, in hypertensive STEMI patients, while
Anavekar et al. [37] showed that moderate renal dysfunction
(predicted by glomerular filtration rate) was associated
with a higher rate of MI complications, in particular heart
failure. It is likely that STEMI hypertensive patients are
more prone to develop a acute renal failure or a contrast
induced nephropathy. A recent study by Thiele et al. [38]
confirmed that in both hypertensive and nonhypertensive
STEMI patients, who undergo coronary angiography and
angioplasty with stenting and moderate doses of contrast
medium, only optimal hydration is effective in preventing a
contrast-induced nephropathy, while N-acetylcysteine only
reduces oxidative stress due to reperfusion after AMI in
comparison with placebo [39]. It can be supposed that
the target mean arterial pressure in hypertensive patients
should be achieved in order to guarantee an adequate renal
perfusion and to prevent acute renal failure.
Cardiogenic shock remains the leading cause of death in
patients hospitalized with acute MI and in particular with
STEMI [40, 41], but its incidence has been greatly reduced by
the use of reperfusion therapy through mechanical revascu-
larization. One of the wider registries including cardiogenic
shock patients, the SHOCK Trial, included 1190 patients
from different countries, of which about 53% had a previous
history of hypertension: overall mortality was decreased in
comparison with previous registries, and the main cause was
ventricular septum rupture [42]. These data agree with our
experience in patients with cardiogenic shock treated with
IABP (hypertension was detectable in 51.3% of the entire
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population) [43]. Free wall and interventricular septum
ruptures occur more frequently in elderly patients of female
sex, in previously known hypertensive patients [44] and in
those who suffer from their first acute myocardial infarction,
with a preferential involvement of left ventricle and anterior
wall at the junction of the infarct and normal muscle. Partial
or total rupture of a papillary muscle is more rare but
often fatal and can be caused by an inferior wall infarction
with involvement of posteromedial papillary muscle: partial
rupture (tip or head of muscle) causes a massive but not
immediately fatal mitral regurgitation (MR) while total
rupture can lead to death (acute massive MR). In all these
conditions, especially in patients with previously known and
poorly controlled hypertensive state, high blood pressure
values could play a pivotal role as they highly increase
intracavitary pressures and shear stress force of muscular
contraction against an inert and necrotic area, leading to
laceration and then to rupture [45]. This strengthens the
importance of a strict blood pressure control, in the first
hours after an acute myocardial infarction. Specific data on
the rate of hemodynamic and bioelectric complications of an
acute MI in hypertensive patients are scarce and inconsistent.
Mauri et al. [46] have reported that a history of hypertension
in AMI was associated with an increased incidence of sudden
death. On the other hand, Abrignani et al. [47] found a lower
incidence of shock, ventricular fibrillation, atrioventricular
conduction disturbances, intracardiac thrombus, and cardiac
rupture in hypertensive patients suffering from STEMI,
while atrial fibrillation was more common in these patients.
More recently, in the paper by Rembek et al., hypertensive
STEMI patients showed higher incidence of cardiogenic
shock, pulmonary oedema, ventricular tachycardia and/or
fibrillation and third degree atrioventricular block; they
required intraaortic balloon counterpulsation (IABP) more
than nonhypertensive STEMI patients [35].
Our group recently evaluated [48] the role of prior and
new anaemia and their prognostic significance in the short
term in STEMI patients. Hypertension was present in 53%
of patients, and “new anemia” patients were more frequently
affected by hypertension (56.5%), followed by prior anemia
(55.3%, P < .05) and normal Hb (46.2%, P < .05).
This strongly suggests that hypertensive STEMI patients are
a “high-risk” population with a higher risk of developing
bleeding complications and a higher mortality rate.
Lastly, hypertensive patients with STEMI are more likely
to be affected by type 2 diabetes [35], and, if without
previously known diabetes, they show elevated blood glucose
levels on admission, which is known to negatively affect
prognosis. In a recent study by Lazzeri et al. [49] on
elderly STEMI patients (>75 years), increased glucose values
were independent predictors of early death. Prevalence of
hypertension was 71% in females and 65.2% in males,
respectively. A subanalysis of the Acute Myocardial Infarction
Registry (KAMIR), which collected a total of 8568 Korean
patients with STEMI, confirmed that presence of type 2
diabetes in hypertensive STEMI patients is very common and
is associated with worse clinical and angiographic features
with a higher risk to develop heart failure and an increased
risk of MACE on long-term followup [50].
5. Hypertension in STEMI: Prognosis
Several studies reported that a history of hypertension was
associated with an increased rate of adverse outcomes after
AMI such as stroke, heart failure, and cardiovascular death
[6, 10]. The increased incidence of AMI or sudden death in
hypertensive patients may be related to several factors, such
as endothelial damage, atherosclerosis, insulin resistance, left
ventricular hypertrophy, and ventricular arrhythmias [23].
In the KAMIR study 48% of STEMI patients had hyper-
tension: at multivariate analysis a history of hypertension
independently contributed to higher in-hospital mortality in
patients with AMI but not to one-year mortality. This was
related not to antecedent hypertension but to the coexistence
of other risk factors (old age, high Killip class, multivessel
disease) [51]. Multivessel disease and complex lesions in
coronary angiography are among the factors which have been
proved to be associated with poor outcomes in hypertensive
patients [52].
In the GISSI-2 study, in-hospital and 6-month mortality
in hypertensive MI patients was significantly higher com-
pared to normotensive patients [15] as was the rate of left
ventricular failure, recurrent angina, and recurrent MI. On
the other hand, GUSTO-1 study showed that elevated blood
pressure was not an independent prognostic factor for 30-
day mortality, but in these trial patients with very high values
of blood pressure were excluded due to the thrombolytic
treatment [14]. A later subanalysis of the GUSTO-1 trial [53]
found a higher risk of early death in patients with elevated
systolic blood pressure (BP) at admission.
On the other side, Abrignani et al. [47] stated that hyper-
tensive subjects with first AMI have a better in-hospital out-
come than age- and gender-matched normotensive subjects,
perhaps due to a less severe extension of the infarction area
or to a different physiopathologic mechanism. Other studies
did not show relevant difference for in-hospital and 6-month
mortality in hypertensive and normotensive patients with
myocardial infarction [35, 54], even considering different
subgroups according to BP admission values (normal, high-
normal, high) [55].
In the PROVE-IT-TIMI 22 trial (PRavastatin Or ator-
Vastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction) 4162 patients with ACS were cate-
gorized in 10 mm Hg increments of blood pressure during
followup: a J- or U-shaped curve association was found
between blood pressure and risk of future cardiovascular
events, with the lowest event rates in the systolic pressure
(SBP) range of 130 to 140 mm Hg and 80 to 90 mm Hg
diastolic pressure (DBP), a flat curve for 110–130 mm Hg
SBP and 70–90 mm Hg BDP. The latter finding strongly
suggests that too low pressures (especially <110/70 mm
Hg) may be dangerous; anyway the trial considered only
blood pressure values during follow-up visits, not in-hospital
measurements [56].
Most of the studies regarding links between hypertension
and myocardial infarction consider patients with a previous
history of hypertension, but few data are available about
patients who do not have a previously known history of
hypertension but showed elevated blood pressure values
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during their hospital staying for ACS. In patients with
myocardial infarction admitted within 6 hours from the
onset of pain [57], 31.7% presented with elevated blood
pressure (≥160/100 mm Hg): only 6.3% of these patients
had elevated blood pressure levels after 6 hours, though
not treated with any antihypertensive drug. Blood pressure
should therefore be carefully monitored in patients with ACS
for several reasons: (a) to achieve the optimal perfusion
pressure by tailoring drugs, (b) to prevent complications
(ranging from drug-induced hypotension to hypertensive
crisis which may promote acute heart failure syndrome),
and (c) to obtain renal protection (thus preventing acute
renal failure). Whenever the findings of serial high BP
measurements and/or previously not known left ventricular
hypertrophy should lead to the suspicion that a hypertensive
state was present before hospital admission for ACS, a more
strict followup should be recommended in these patients
as well as investigations in order to rule out hypertension-
related complications (i.e., fundus oculi).
6. Recommendations
(1) ACS patients with hypertension represent a subset at
higher risk since they are more often older and with
higher comorbidities (including renal failure).
(2) In these patients blood pressure values should be
carefully monitored in order to achieve an adequate
perfusion pressure (usually values of mean arterial
pressure higher in respect to nonhypertensive ACS
patients). The main goal is to prevent renal failure
due to hypoperfusion.
(3) At echocardiographic evaluation, diastolic function
should be carefully assessed and treated in hyper-
tensive ACS patients. In these patients, hypertensive
crises can lead to the development of acute heart
failure syndrome.
(4) Comorbidities should be “searched” if not previously
diagnosed, firstly, glucose imbalance by means of
serial glucose measurements, acute insulin resis-
tance (by means of HOMA index), and glycated
haemoglobin (indicating the glucose control in the
previous months). The occurrence of anemia on
admission should induce an accurate evaluation of
renal function in order to exclude the coexistence of
renal failure.
(5) In presence of BP values difficult to treat, stenosis of
renal artery should be ruled out.
(6) A strict followup should be recommended in ACS
patients with hypertension with close monitoring of
adherence to drug administration. In fact, polyphar-
macy is quite frequent in hypertensive patients,
especially after ACS, but in these patients the conse-
quences of drug discontinuation may be severe and
even lethal.
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